During controlled ovarian stimulation, premature LH rise occurred in 14% with low-dose cetrorelix versus 10% with standard-dose cetrorelix, without statistical difference.
In plain wordsDuring ovarian stimulation, premature LH rise occurred in 14% with low-dose cetrorelix versus 10% with standard-dose cetrorelix, without statistical difference.
- Peptide
- Cetrorelix
- Outcome
- No significant changePremature LH rise
- Study
n = 76
- Comparator
- Cetrorelix 0.25 mg/day
- Outcome group
- Sex hormones and fertility · Endocrine and hormones
- Studied dose
- 0.125 mg/day · injectionAs given in this study (human).
Measurements
- Premature LH rise incidence
- 14%
- 0.125 mg/day
- Premature LH rise incidence
- 10%
- 0.25 mg/day
Source sentences
Premature LH rise was recorded in 10% of patients injecting antagonist at 0.25 mg/day and in 14% of patients administered with antagonist at 0.125 mg/day. These frequencies did not differ statistically.
3 context sentences(design, population, supporting numbers)
The current prospective randomized study was designed to test the efficacy of a low dose (0.125 mg/day) of the gonadotrophin-releasing hormone antagonist cetrorelix in preventing premature luteinizing hormone (LH) rise during controlled ovarian stimulation in comparison with the standard dose of 0.25 mg/day.
Cetrorelix was injected daily from day 6 of gonadotropin administration.
There were 40 patients receiving cetrorelix at 0.25 mg/day and 36 patients receiving cetrorelix at 0.125 mg/day.